Michael Powell

This profile gathers the share dealings of Michael Powell across 7 companies, led by Orexigen Therapeutics, Inc., Ocera Therapeutics, Inc. and Trius Therapeutics Inc. In total, 99 filings cover trades dated from 15 December 2005 to 11 August 2020.

In open-market terms, that means 9 purchases worth €22.4M on one side and 54 sales worth €46.6M on the other. On balance, insiders were net sellers of €24.2M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 7 share grants and 2 option exercises. So far in 2020, the count stands at 1 purchase and no sales.

A typical purchase (the median) is worth €1.5M.

The newest entry dates from 12 August 2020: an open-market purchase of €1.7M, in Checkmate Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.